Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary micro-circulation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546–1550.
Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90: 1248–1253.
Clarkson P, Adams MR, Powe Ai, Donald AE, McCredie R, Robinson J, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996; 97: 1989–1994.
Böger RH, Mugge A, Bode-Böger SM, Heinzel D, Hoper MM, Frolich JC. Differential systemic and pulmonary hemodynamic effects of L-arginine in patients with coronary artery disease or primary pulmonary hypertension. Int J Clin Pharmacol Ther 1996; 34: 323–328.
Malczewska-Malec M, Goldsztajn P, Kawecka-Jaszcz K, Czarnecka D, Siedlecki A, Siemienska T, et al. Effects of prolonged L-arginine administration on blood pressure in patients with essential hypertension (EH). Agents Actions 1995; 45 (Suppl): 157–162.
Pagnatta P, Germano G, Grutter G, Leonardo F, Rosano GM, Chieria SL. Oral L-arginine supplementation improves essential hypertension. Circulation 1997; 96: I - 538.
Smulders RA, Stehouwer CD, Olthof CG, van Kamp GJ, Teerlink, T, de Vries PM, et al. Plasma endothelin levels and vascular effects of intravenous L-arginine infusion in subjects with uncomplicated insulin-dependent diabetes mellitus. Clin Sci (Colch) 1994; 87: 37–43.
Lubec B, Hayn M, Kitzmuller E, Vierhapper H, Lubec G. L-Arginine reduces lipid peroxidation in patients with diabetes mellitus. Free Rad Biol Med 1997; 22: 355–357.
Adams MR, Jessup W, Celermajer DS. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol 1997; 29: 491–497.
Chauhan A, More RS, Mullins PA, Taylor G, Petch C, Schofield PM. Aging-associated endothelial dysfunction in humans is reversed by L-arginine. J Am Coll Cardiol 1996; 28: 1796–1804.
Higashi Y, Oshima T, Watanabe M, Matsuura H, Kajiyama G. Renal response to L-arginine in salt-sensitive patients with essential hypertension. Hypertension 1996; 27: 643–648.
Higashi Y, Oshima T, Ozono R, Watanabe M, Matsuura H, Kajiyama G. Effects of L-arginine infusion on renal hemodynamics in patients with mild essential hypertension. Hypertension 1995; 25: 898–902.
Campese VM, Amar M, Anjali C, Medhat T, Wurgaft A. Effect of L-arginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension. J Hum Hypertens 1997; 11: 527–532.
McCaffrey MJ, Bose CL, Reiter PD, Stiles AD. Effect of L-arginine infusion on infants with persistent pulmonary hypertension of the newborn. Biol Neonate 1995; 67: 240–243.
Mehta S, Stewart DJ, Langleben D, Levy RD. Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. Circulation 1995; 92: 1539–1545.
Surdacki A, Zmudka K, Bieron K, Kostka-Trabka E, Dubiel JS, Gryglewski RJ. Lack of beneficial effects of L-arginine infusion in primary pulmonary hypertension. Wien Klin Wochenschr 1994; 106: 521–526.
Adams MR, Jessup W, McCredie R, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. J Am Coll Cardiol 1997; 29: 387A.
Dubois-Rande JL, Zelinsky R, Chabrier PE, Castaigne A, Geschwind H, Adnot S. L-arginine improves endothelium-dependent relaxation of conductance and resistance coronary arteries in coronary artery disease. J Cardiovasc Pharmacol 1992; 20 (Suppl 12): S211–5213.
Tagawa H, Mohri M, Ichiki T, Egashira K. L-arginine attemuates tachycardia-induced mayocardial ischemia in patients with extensive coronary artery disease. Circulation 1997; I (Suppl): 1–550.
Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997; 129: 261–269.
Bode-Böger SM, Böger RH, Thiele W, Creutzig A, Frolich JC. L-arginine infusion therapy restores vascular NO production and improves the symptoms of intermittent claudication in patients with peripheral arterial disease. Circulation 1997; 96: 1–419.
Schellong SM, Böger RH, Burchert W, Bode-Böger SM, Galland A, Frölich JC, et al. Dose-related effect of intravenous L-arginine on muscular blood flow of the calf in patients with peripheral vascular disease: a H215O positron emission tomography study. Clin Sci (Colch) 1997; 93: 159–165.
Bode-Böger SM, Böger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation 1996; 93: 85–90.
Wascher TC, Bahadori B, Habersack-Wallner S, Toplak H. Oral L-arginine supplementation in chronic heart failure. Circulation 1997; 95: 1674–1675.
Kubota T, Imaizumi T, Oyama J, Ando S, Takeshita A. L-arginine increases exercise-induced vasodilation of the forearm in patients with heart failure. Jpn Circ J 1997; 61: 471–480.
Hirooka Y, Imaizumi T, Tagawa T, Shiramoto M, Endo T, Ando S, et al. L-arginine on impaired acetylholine-induced and ischemic vasodilation of the forearm in patients with heart failure. Circulation 1994; 90: 658–668.
Rector TS, Bank AJ, Mullen KA, Tschmumperlin LK, Sih R, Pillai K, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93: 2135–2141.
Chin-Dusting JP, Kaye DM, Lefkovits J, Wong J, Bergin P, Jennings GL. Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 1996; 27: 1207–1213.
Drexler H, Fischell TA, Pinto FJ, Chenzbraun A, Botas J, Cooke JP, et al. Effect of L-arginine on coronary endothelial function in cardiac transplant recipients. Relation to vessel wall morphology. Circulation 1994; 89: 1615–1623.
Paulus WJ, Kastner S, Vanderheyden M, Shah AM, Drexler H. Myocardial contractile effects of L-arginine in the human allograft. J Am Coll Cardiol 1997; 29: 1332–1338.
Ebel M, Catapano G, Colombo MG, Clerico A, Giannessi D, del Chicca M, et al. The humoral, renal and pressor effects of systemic L-arginine infusion in hypertensive patients. J Hypertens 1993; 11 (Suppl 5): S140 - S141.
Wolf SC, Erley CM, Kenner S, Berger ED, Risler T. Does L-arginine alter proteinuria and renal hemodynamics in patients with chronic glomerulonephritis and hypertension? Clin Nephrol 1995; 43 (Suppl 1): S42 - S46.
Hand MF, Haynes WG, Webb DJ. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int 1998; 53: 1068–1077.
Agostoni A, Marasini B, Biondi ML, Bassani C, Cazzaniga A, Bottasso B, et al. L-arginine therapy in Raynaud’ s phenomenon? International Journal of Clin Lab Res 1991; 21: 202–203.
Khan F, Litchfield SJ, McLaren M, Veale DJ, Littleford RC, Belch JJ. Oral L-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud’s phenomenon. Arthritis Rheum 1997; 40: 352–357.
Zorgniotti AW, Lizza EF. Effect of large doses of the nitric oxide precursor, L-arginine, on erectile dysfunction. Int J Impot Res 1994; 6: 33–35.
Moody JA, Vernet D, Laidlaw S, Rajfer J, Gonzalez-Cadavid NF. Effects of long-term oral administration of L-arginine on the rat erectile response. J Urol 1997; 158: 942–947.
Jovanovic A, Grbovic L, Tulic I. L-arginine induces relaxation of human uterine artery with both intact and denuded endothelium. Eur J Pharmacol 1994; 256: 103–107.
Byrne BM, Howard RB, Morrow RJ, Whiteley KJ, Adamson SL. Role of the L-arginine nitric oxide pathway in hypoxic fetoplacental vasoconstriction. Placenta 1997; 18: 627–634.
Neri I, Mazza V, Galassi MC, Volpe A, Facchinetti F. Effects of L-arginine on utero-placental circulation in growth-retarded fetuses. Acta Obstet Gynecol Scand 1996; 75: 208–212.
Aji W, Ravalli S, Szabolcs M, Jiang XC, Sciacca RR, Michler RE, et al. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice. Circulation 1997; 95: 430–437.
Böger RH, Bode-Böger SM, Brandes RP, Phivthong-ngam L, Bohme M, Nafe R, et al. Dietary Larginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96: 1282–1290.
Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscl Thromb Vasc Biol 1996; 16: 44–50.
Schwarzacher SP, Lim TT, Wang B, Kernoff RS, Niebauer J, Cooke JP, et al. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation 1997; 95: 1863–1869.
Greenlees C, Wadsworth RM, Martorana PA, Wainwright CL. The effects of L-arginine on neointimal formation and vascular function following balloon injury in heritable hyperlipidaemic rabbits. Cardiol Res 1997; 35: 351–359.
McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993; 193: 291–296.
Carrier M, Khalil A, Tourigny A, Solymoss BC, Pelletier LC. Effect of L-arginine on metabolic recovery of the ischemic myocardium. Ann Thorac Surg 1996; 61: 1651–1657.
Engelman DT, Watanabe M, Maulik N, Cordis GA, Engelman RM, Rousou JA, et al. L-arginine reduces endothelial inflammation and myocardial stunning during ischemia/reperfusion. Ann Thorac Surgery 1995; 60: 1275–1281.
Shiraishi Y, Lee JR, Laks H, Waters PF, Meneshian A, Blitz A, et al. L-arginine administration during reperfusion improves pulmonary function. Ann Thorac Surgery 1996; 62: 1580–1587.
Wang QD, Morcos E, Wiklund P, Pernow J. L-arginine enhances functional recovery and Ca(2+)dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart. J Cardiovasc Pharmacol 1997; 29: 291–296.
Sporer B, Martens KH, Koedel U, Haberl RL. L-arginine-induced regional cerebral blood flow increase is abolished after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1997; 17: 1074–1080.
Nilsson B, Yoshida T, Delbro D, Andius S, Friman S. Pretreatment with L-arginine reduces ischemia/ reperfusion injury of the liver. Transplant Proc 1997; 29: 3111–3112.
Ferraresso M, Burra P, Cadrobbi R, Calabrese F, Pettenazzo E, Sarzo G, et al. Protective effect of L-arginine on liver ischemia-reperfusion injury. Transplant Proc 1997; 29: 393–394.
Amrani M, Gray CC, Smolenski RT, Goodwin AT, London A, Yacoub MH. The effect of L-arginine on myocardial recovery after cardioplegic arrest and ischemia under moderate and deep hypothermia. Circulation 1997;96: II-274-II-279.
Zhu B, Sun Y, Sievers RE, Glantz SA, Chatterjee K, Parmley WW. L-arginine decreases infarct size in rats exposed to environmental tobacco smoke. Am Heart J 1996; 132: 91–100.
Barbul A, Rettura G, Levenson SM, Seifter E. Arginine: a thymotropic and wound-healing promoting agent. Surg Forum 1997; 28: 101–103.
Park KG, Hayes PD, Garlick Pi, Sewell H, Eremin O. Stimulation of lymphocyte natural cytotoxicity by L-arginine. Lancet 1991; 337: 645–646.
Imler M, Ruscher H, Peter B, Kurtz D, Stahl J. [Action of arginine in a recurrent hepatic coma complicating a feminizing tumor of the adrenal cortex with hepatic metastases]. Sem Hop 1973; 49: 3183–3190.
Batshaw ML, Wachtel RC, Thomas GH, Starrett A, Brusilow SW. Arginine-responsive asymptomatic hyperammonemia in the premature infant. J Pediatr 1984; 105: 86–91.
Bellone J, Bartolotta E, Cardinale G, Arvat E, Cherubini V, Aimaretti G, et al. Low dose orally administered arginine is able to enhance both basal and growth hormone-releasing hormone-induced growth hormone secretion in normal short children. J Endo Invest 1993; 16: 521–525.
Brittenden J, Heys SD, Eremin O. L-arginine and malignant disease: a potential therapeutic role? Eur J Surg Oncol 1994; 20: 189–192.
Rhodes P, Barr CS, Struthers AD. Arginine, lysine and ornithine as vasodilators in the forearm of man. Eur J Clin Invest 1996; 26: 325–331.
Thomas G, Hecker M, Ramwell PW. Vascular activity of polycations and basic amino acids: L-arginine does not specifically elicit endothelium-dependent relaxation. Biochem Biophys Res Commun 1989; 158: 177–180.
Wascher TC, Posch K, Wallner S, Hermetter A, Kostner GM, Graier WF. Vascular effects of L-arginine: anything beyond a substrate for the NO-synthase? Biochem Biophys Res Commun 1997; 234: 35–38.
Korbonits M, Trainer PJ, Fanciulli G, Oliva O, Pala A, Dettori A, et al. L-arginine is unlikely to exert neuroendocrine effects in humans via the generation of nitric oxide. Eur J Endo 1996; 135: 543–547.
Blachier F, Mourtada A, Sener A, Malaisse WJ. Stimulus-secretion coupling of arginine-induced insulin release. Uptake of metabolized and nonmetabolized cationic amino acids by pancreatic islets. Endocrinology 1989; 124: 134–141.
Reyes AA, Karl IE, Klahr S. Role of arginine in health and in renal disease. Am J Physiol 1994; 267: F331 - F346.
Kirk SJ, Hurson M, Regan MC, Holt DR, Wasserkrug HL, Barbul A. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 1993; 114: 155–160.
Pegg AE, McCann PP. Polyamine metabolism and function. Am J Physiol 1982; 243: C212 - C221.
Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480–10484.
Visek WJ. Arginine and disease states. J Nutr 1985; 115: 532–541.
Hanssen H, Brunini TM, Conway M, Banning AP, Roberts NB, Ellory JC, et al. Increased L-arginine transport in human erythrocytes in chronic heart failure. Clin Sci (Colch) 1998; 94: 43–48.
FAO/WHO/UNU. Energy and Protein Requirements. Technical Report Series. WHO, Geneva, Switzerland, 1985.
Walser M. Urea cycle disorders and other hereditary hyperammonemic syndromes. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The Metabolic Basis of Inherited Disease. McGraw-Hill, New York, 1983, pp. 402–438.
Visek WJ. Arginine needs, physiological state and usual diets. A reevaluation. J Nutr 1986; 116: 36–46.
Aisaka K, Gross SS, Griffith OW, Levi R. NG-methylarginine, an inhibitor of endothelium-derived nitric oxide synthesis, is a potent pressor agent in the guinea pig: does nitric oxide regulate blood pressure in vivo? Biochem Biophys Res Commun 1989; 160: 881–886.
Aisaka K, Gross SS, Griffith OW, Levi R. L-arginine availability determines the duration of acetylcholine-induced systemic vasodilation in vivo. Biochem Biophys Res Commun 1989; 3: 710–717.
Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375–3378.
Girerd XJ, Hirsch AT, Cooke JP, Dzau VJ, Creager MA. L-arginine augments endothelium-dependent vasodilation in cholesterol-fed rabbits. Circ Res 1990; 67: 1301–1308.
Cooke JP, Andon NA, Girerd XJ, Hirsch AT, Creager MA. Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation 1991; 83: 1057–1062.
Sato H, Zhao ZQ, Vinten-Johansen J. L-Arginine inhibits neutrophil adherence and coronary artery dysfunction. Cardiovasc Res 1996; 31: 63–72.
Singer AH, Tsao PS, Wang BY, Bloch DA, Cooke JP. Discordant effects of dietary L-arginine on vascular structure and reactivity in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1995; 25: 710–716.
Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 1994; 89: 2176–2182.
Tsao PS, Theilmeier G, Singer AH, Leung LL, Cooke JP. L-arginine attenuates platelet reactivity in hypercholesterolemic rabbits. Arterioscl Thromb 1994; 14: 1529–1533.
Liu J, Garcia-Cardena G, Sessa WC. Palmitoylation of endothelial nitric oxide synthase is necessary for optimal stimulated release of nitric oxide: implications for caveolae localization. Biochemistry 1996; 35: 13277–13281.
Palmer RM, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989; 158: 348–352.
Baydoun AR, Emery PW, Pearson JD, Mann GE. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun 1990; 73: 940–948.
Gold ME, Bush PA, Ignarro U. Depletion of arterial L-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 1989; 164: 714–721.
Hecker M, Mitchell JA, Harris HJ, Katsura M, Thiemermann C, Vane JR. Endothelial cells metabolize NG-monomethyl-L-arginine to L-citrulline and subsequently to L-arginine. Biochem Biophys Res Commun 1990; 167: 1037–1043.
Arnal JF, Munzel T, Venema RC, James NL, Bai CL, Mitch WE, et al. Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. J Clin Invest 1995; 95: 2565–2572.
Förstermann U, Closs EI, Pollock JS, Nakane M, Schwartz P, Gath I, et al. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121–1131.
Sessa WC, Hecker M, Mitchell JA, Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proc Natl Acad Sci USA 1990; 87: 8607–8611.
Hecker M, Sessa WC, Harris HJ, Anggard EE, Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci USA 1990; 87: 8612–8616.
Swierkosz TA, Mitchell JA, Sessa WC, Hecker M, Vane JR. L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta. Biochem Biophys Res Commun 1990; 172: 143–148.
Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3’:5’-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 1977; 74: 3203–3207.
McDonald KK, Zharikov S, Block ER, Kilberg MS. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the “arginine paradox. ” J Biol Chem 1997; 272: 31213–31216.
Garcia-Cardena G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci USA 1996; 93: 6448–6453.
Zharikov SI, Block ER. Characterization of L-arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells. Biochim Biophys Acta 1998; 1369: 173–183.
Greene B, Pacitti Ai, Souba WW. Characterization of L-arginine transport by pulmonary artery endothelial cells. Am J Physiol 1993; 264: L351 - L356.
Kavanaugh MP. Voltage dependence of facilitated arginine flux mediated by the system y+ basic amino acid transporter. Biochemistry 1993; 32: 5781–5785.
Wang H, Kavanaugh MP, North RA, Kabat D. Cell-surface receptor for ecotropic murine retroviruses is a basic amino-acid transporter [see comments]. Nature 1991; 352: 729–731.
Zharikov SI, Herrera H, Block ER. Role of membrane potential in hypoxic inhibition of L-arginine uptake by lung endothelial cells. Am J Physiol 1997; 272: L78 - L84.
Sobrevia L, Yudilevich DL, Mann GE. Activation of A2-purinoceptors by adenosine stimulates L-arginine transport (system y+) and nitric oxide synthesis in human fetal endothelial cells. J Physiol (Lond) 1997; 499: 135–140.
Sobrevia L, Mann GE. Dysfunction of the endothelial nitric oxide signalling pathway in diabetes and hyperglycaemia. Exp Physiol 1997; 82: 423–452.
Cendan JC, Moldawer LL, Souba WW, Copeland EM, Lind DS. Endotoxin-induced nitric oxide production in pulmonary artery endothelial cells is regulated by cytokines. Arch Surg 1994; 129: 1296–1300.
Cendan JC, Souba WW, Copeland EM, Lind DS. Cytokines regulate endotoxin stimulation of endothelial cell arginine transport. Surgery 1995; 117: 213–219.
Lind DS, Copeland EM 3rd, Souba WW. Endotoxin stimulates arginine transport in pulmonary artery endothelial cells. Surgery 1993; 114: 199–205.
Sobrevia L, Nadal A, Yudilevich DL, Mann GE. Activation of L-arginine transport (system y+) and nitric oxide synthase by elevated glucose and insulin in human endothelial cells. J Physiol (Lond) 1996; 490: 775–781.
Sobrevia L, Cesare P, Yudilevich DL, Mann GE. Diabetes-induced activation of system y+ and nitric oxide synthase in human endothelial cells: association with membrane hyperpolarization. J Physiol (Lond) 1995; 489: 183–192.
Chen LY, Mehta P, Mehta JL. Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets: relevance of the effect of oxidized LDL on platelet function. Circulation 1996; 93: 1740–1746.
Valiance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572–575.
MacAllister RJ, Parry H, Kimoto M, Collier J, Moncada S. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1–8.
Bode-Böger SM, Boger RH, Kienke S, Junker W, Frolich JC. Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598–603.
Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, et al. Restoration of L-arginine/ADMA ratio normalizes mononuclear leukocyte adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol, in press.
Böger R, Bode Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric Dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847.
Faraci FM, Brian JE Jr, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269: H1522 - H1527.
MacAllister RJ, Fickling SA, Whitley GS, Valiance P. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis. Br J Pharmacol 1994; 112: 43–48.
Mendes Ribeiro AC, Hanssen H, Kiessling K, Roberts NB, Mann GE, Ellory JC. Transport of L-arginine and the nitric oxide inhibitor NG-monomethyl-L-arginine in human erythrocytes in chronic renal failure. Clin Sci (Colch) 1997; 93: 57–64.
Bogle RG, MacAllister RJ, Whitley GS, Valiance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol 1995; 269: C750 - C756.
Pritchard KA Jr, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res 1995; 77: 510–518.
Huk I, Nanobashvili J, Neumayer C, Punz A, Mueller M, Afkhampour K, et al. L-arginine treatment alters the kinetics of nitric oxide and superoxide release and reduces ischemia/reperfusion injury in skeletal muscle. Circulation 1997; 96: 667–675.
Stroes E, Kastelein J, Cosentino F, Erkelens W, Weyer R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41–46.
Schini VB, Vanhoutte PM. L-arginine evokes both endothelium-dependent and -independent relaxations in L-arginine-depleted aortas of the rat. Circ Res 1991; 68: 209–216.
Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt RJ. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys 1995; 323: 279–287.
Liu Z, Perlin AS. Regioselectivity in the sulfation of some chemically-modified heparins, and observations on their cation-binding characteristics. Carb Res 1992; 236: 121–133.
Fajans SS, Floyd JC Jr, Knopf RF, Conn FW. Effect of amino acids and proteins on insulin secretion in man. Recent Prog Horm Res 1967; 23: 617–662.
Giugliano D, Marfella R, Verrazzo G, Acampora R, Coppola L, Cozzolino D, et al. The vascular effects of L-arginine in humans The role of endogenous insulin. J Clin Invest 1997; 99: 433–438.
Sanchez A, Hubbard R. Dietary protein modulation of serum cholesterol: the amino acid connection. In: Freidman M, ed. Absorption and Utilization of Amino Acids. CRC Press, New York, 1990, pp. 247–273.
Ness GC, Zhao Z, Wiggins L. Insulin and glucagon modulate hepatic 3-hydroxy-3-methylglutarylcoenzyme A reductase activity by affecting immunoreactive protein levels. J Biol Chem 1994; 269: 29168–29172.
Kritchevsky XX. Dietary protein and atherosclerosis. In: Freidman M, ed. Absorption and Utilization of Amino Acids. CRC Press, New York, 1990, pp. 235–245.
Sirtori CR, Galli G, Lovati MR, Carrara P, Bosisio E, Kienle MG. Effects of dietary proteins on the regulation of liver lipoprotein receptors in rats. J Nutr 1984; 114: 1493–1500.
Barth CA, Pfeuffer M. Dietary protein and atherogenesis. Klin Wochenschr 1988; 66: 135–143.
Kritchevsky D. Protein and atherosclerosis. J Nutr Sci Vitaminol (Tokyo) 1990; 36 (Suppl 2): S81 - S86.
Kurowska EM, Carroll KK. Hypocholesterolemic properties of nitric oxide. In vivo and in vitro studies using nitric oxide donors. Biochim Biophys Acta 1998; 1392: 41–50.
Wascher TC, Graier WF, Dittrich P, Hussain MA, Bahadori B, Wallner S, et al. Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity. EurJ Clin Invest 1997; 27: 690–695.
Miliutina NP, Ananian AA, Shugalei VS. [Antiradical and antioxidant effect of arginine and its action on lipid peroxidation in hypoxia]. Biull Eksp Biol Med 1990; 110: 263–265.
Philis-Tsimikas A, Witztum JL. L-arginine may inhibit atherosclerosis through inhibition of LDL oxidation. Circulation 1995; 92: 1422–1443.
Xiong Y, Li YJ, Deng HW. Protection of 1-arginine against oxygen free radicals-injured rabbit aortic endothelium. Chung Kuo Yao Li Hsueh Pao 1994; 15: 119–123.
Clancy RM, Leszczynska P, Piziak J, Abramson SB. Nitric oxide, an endothelial cell relation factor, inhibits neutrophil superoxide anion production via a direct action of NADPH oxidase. J Clin Invest 1992; 90: 1116–1121.
Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270: 14214–14219.
Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 1997; 96: 934–940.
Higashi Y, Oshima T, Ono N, Hiraga H, Yoshimura M, Watanabe M, et al. Intravenous administration of L-arginine inhibits angiotensin-converting enzyme in humans. J Clin Endocrinol Metab 1995; 80: 2198–2202.
Barbul A, Fishel RS, Shimazu S, Wasserkrug HL, Yoshimura NN, Tao RC, et al. Intravenous hyper-alimentation with high arginine levels improves wound healing and immune function. J Surg Res 1985; 38: 328–334.
Nirgiotis JG, Hennessey PJ, Andrassy RJ. Effects of an arginine-free enteral diet on wound healing and immune function in the postsurgical rat. J Ped Surg 1991; 26: 936–941.
Seifter E, Rettura G, Barbul A, Levenson SM. Arginine: an essential amino acid for injured rats. Surgery 1978; 84: 224–230.
Barbul A, Rettura G, Levenson SM, Seifter E. Wound healing and thymotropic effects of arginine: a pituitary mechanism of action. Am J Clin Nutr 1983; 37: 786–794.
Heys SD, Gough DB, Park KGM, Eremin O. L-arginine: clinical practice and potential applications. In: Eremin O, ed. L-Arginine: Biological Aspects and Clinical Applications. Chapman & Hall, Austin, TX, 1997, pp. 115–157.
Micieli G, Bosone D, Costa A, Cavallini A, Marchesselli S, Pompeo F, et al. Opposite effects of L-arginine and nitroglycerin on cerebral blood velocity: nitric oxide precursors and cerebral blood velocity. J Neurol Sci 1997; 150: 71–75.
Reutens DC, McHugh MD, Toussaint PJ, Evans AC, Gjedde A, Meyer E, et al. L-arginine infusion increases basal but not activated cerebral blood flow in humans. J Cereb Blood Flow Metab 1997; 17: 309–315.
Cooke JP, Dzau J, Creager A. Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. Basic Res Cardiol 1991; 86 (Suppl 2): 173–181.
Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168–7112.
Davies MG, Dalen H, Kim JH, Barber L, Svendsen E, Hagen PO. Control of accelerated vein graft atheroma with the nitric oxide precursor: L-arginine. J Surg Res 1995; 59: 35–42.
Jeremy RW, McCarron H, Sullivan D. Effects of dietary L-arginine on atherosclerosis and endothelium-dependent vasodilatation in the hypercholesterolemic rabbit. Response according to treatment duration, anatomic site, and sex. Circulation 1996; 94: 498–506.
Randall MD, Ujiie H, Griffith TM. L-arginine reverses the impairment of nitric oxide-dependent collateral perfusion in dietary-induced hypercholesterolaemia in the rabbit. Clini Sci (Colch) 1994; 87: 53–59.
Rossitch E Jr, Alexander ED, Black PM, Cooke JP. L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J Clin Invest 1991; 87: 1295–1299.
Schuschke DA, Miller FN, Lominadze DG, Feldhoff RC. L-arginine restores cholesterol-attenuated microvascular responses in the rat cremaster. Int J Microcirc Clin Exp 1994; 14: 204–211.
Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine. Circ Res 1992; 70: 465–476.
Clarkson PB, Lim PO, MacDonald TM. Influence of basal nitric oxide secretion on cardiac function in man. Br J Clin Pharmacol 1995; 40: 299–305.
Chowienczyk PJ, Watts GF, Cockcroft JR, Brett SE, Ritter JM. Sex differences in endothelial function in normal and hypercholesterolaemic subjects. Lancet 1994; 344: 305, 306.
Stroes ES, Koomans HA, de Bruin TW, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467–471.
Goode GK, Heagerty AM. In vitro responses of human peripheral small arteries in hypercholesterolemia and effects of therapy. Circulation 1995; 91: 2898–2903.
Wennmalm A. Endothelial nitric oxide and cardiovascular disease. J Int Med 1994; 35: 317–327.
Casino PR, Kilcoyne CM, Quyyumi AA, Hoeg JM, Panza JA. Investigation of decreased availability of nitric oxide precursor as the mechanism responsible for impaired endothelium-dependent vasodilation in hypercholesterolemic patients. J Am Coll Cardiol 1994; 23: 844–850.
Maxwell AJ, Anderson B, Cooke JP. Endothelial dysfunction in hypercholesterolemia is reversed by a nutritional product designed to enhance nitric oxide activity. Cardiovasc Drugs Ther, in press.
Taddei S, Virdis A, Mattei P, Ghiadoni L, Sudano I, Salvetti A. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996; 94: 1298–1303.
Kitazono T, Faraci FM, Heistad DD. L-arginine restores dilator responses of the basilar artery to acetylcholine during chronic hypertension. Hypertension 1996; 27: 893–896.
Hayakawa H, Hirata Y, Suzuki E, Kimura K, Kikuchi K, Nagano T, et al. Long-term administration of L-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 23: 752–756.
Hind JM, Doodson AC. Oral L-arginine supplementation has no effect on cardiovascular responses to lower body negative pressure in man. Clin Auton Res 1994; 4: 293–297.
Rosano GM, Panina G, Cerquetani E, Leonardo F, Pelliccia F, Bonfigli B, et al. L-arginine improves endothelial function in newly diagnosed hypertensives. J Am Coll Cardiol 1998; 31: 262A (abstract).
Adnot S, Raffestin B, Eddahibi S, Braquet P, Chabrier PE. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991; 87: 155–162.
Fineman JR, Chang R, Soifer SJ. L-Arginine, a precursor of EDRF in vitro, produces pulmonary vasodilation in lambs. Am J Physiol 1991; 261: H1563 - H1569.
Eddahibi S, Adnot S, Carville C, Blouquit Y, Raffestin B. L-arginine restores endothelium-dependent relaxation in pulmonary circulation of chronically hypoxic rats. Am J Physiol 1992; 263: L194 - L200.
Hui S, Mei Q, Qiu B. Effects of chronic nicotine ingestion on pressor response to N omega-nitro-L-arginine methyl ester and ex vivo concentration and relaxation response of aorta to L-arginine. Pharmacol Res 1997; 36: 451–456.
Hutchison SJ, Reitz MS, Sudhir K, Sievers RE, Zhu BQ, Sun YP, et al. Chronic dietary L-arginine prevents endothelial dysfunction secondary to environmental tobacco smoke in normocholesterolemic rabbits. Hypertension 1997; 29: 1186–1191.
Zeiher AM, Schachinger V, Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 1995; 92: 1094–1100.
Thorne S, Mullen MJ, Clarkson P, Donald AE, Deanfield JE. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998; 32: 110–116.
Watts GF, O’Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Colch) 1996; 91: 567–573.
Nitenberg A, Ledoux S, Attali JR, Valensi P. [Response of the coronary arteries to cold test and flow velocity increase is improved by deferoxamine but not by L-arginine in diabetic patients]. Arch Mal Coeur Vaiss 1997; 90: 1037–1041.
Pieper GM, Siebeneich W, Moore-Hilton G, Roza AM. Reversal by L-arginine of a dysfunctional arginine/nitric oxide pathway in the endothelium of the genetic diabetic BB rat. Diabetologia 1997; 40: 910–915.
Mayhan WG, Patel KP, Sharpe GM. Effect of L-arginine on reactivity of hamster cheek pouch arterioles during diabetes mellitus. Int J Microcirc Clin Exp 1997; 17: 107–112.
Pieper GM, Peltier BA. Amelioration by L-arginine of a dysfunctional arginine/nitric oxide pathway in diabetic endothelium. J Cardiovasc Pharmacol 1995; 25: 397–403.
Pieper GM, Siebeneich W, Dondlinger LA. Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur J Pharmacol 1996; 317: 317–320.
Mayhan WG, Didion SP, Patel KP. L-Arginine does not restore dilatation of the basilar artery during diabetes mellitus. J Cereb Blood Flow Metab 1996; 16: 500–506.
Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321 - H326.
Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998; 97: 736–743.
MacAllister RJ, Calver AL, Collier J, Edwards CM, Herreros B, Nussey SS, et al. Vascular and hormonal responses to arginine: provision of substrate for nitric oxide or non-specific effect? Clin Sci (Colch) 1995; 89: 183–190.
Makimattila S, Mantysaari M, Groop PH, Summanen P, Virkamaki A, Schlenzka A, et al. Hyperreactivity to nitrovasodilators in forearm vasculature is related to autonomic dysfunction in insulin-dependent diabetes mellitus. Circulation 1997; 95: 618–625.
Knock GA, McCarthy AL, Lowy C, Poston L. Association of gestational diabetes with abnormal maternal vascular endothelial function. Br J Obstet Gynaecol 1997; 104: 229–234.
Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997; 95: 1783–1790.
Paolisso G, Tagliamonte MR, Marfella R, Verrazzo G, D’ Onofrio F, Giugliano D. L-arginine but not D-arginine stimulates insulin-mediated glucose uptake. Metabolism 1997; 46: 1068–1073.
Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest 1993; 92: 652–662.
Grisham MB, Miles AM. Effects of aminosalicylates and immunosuppressive agents on nitric oxide-dependent N-nitrosation reactions. Biochem Pharmacol 1994; 47: 1897–1902.
Cosentino F, Katusic ZS. Tetrahydrobiopterin and dysfunction of endothelial nitric oxide synthase in coronary arteries. Circulation 1995; 91: 139–144.
Schaffner A, Blau N, Schneemann M, Steurer J, Edgell CJ, Schoedon G. Tetrahydrobiopterin as another EDRF in man. Biochem Biophys Res Commun 1994; 205: 516–523.
Balligand JL, Godfraind T. Endothelium-derived relaxing factor and muscle-derived relaxing factor in rat aorta: action of cyclosporin A. J Cardiovasc Pharmacol 1991; 17: S213 - S221.
Mathieu P, Carrier M, Dupuis J, Ryan J, Pelletier LC. L-arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. Ann Thorac Sur 1997; 64: 414–420.
Gallego MJ, Lopez Fane A, Riesco A, Monton M, Grandes SM, Barat A, et al. Blockade of endothelium-dependent responses in conscious rats by cyclosporin A: effect of L-arginine Am J Physiol 1993; 264: H708 - H714.
Kim HS, Kim DH, Kang SW, Choi H, Lee HY, Han DS, et al. L-arginine restores suppressed acetylcholine-induced endothelium-dependent vascular relaxation in cyclosporine A-treated rats. Transplant Proc 1996; 28: 1372–1374.
Harrison DG, Kurz MA, Quillen JE, Sellke FW, Mugge A. Normal and pathophysiologic considerations of endothelial regulation of vascular tone and their relevance to nitrate therapy. Am J Cardiol 1992; 70: 11B - 17B.
Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995; 95: 187–194.
Abou-Mohamed G, Kaesemeyer WH, Papapetropoulos A, Catravas JD, Caldwell RW. Nitroglycerin (NTG) but not sodium nitroprusside (SNP), increases aortic ring cGMP levels via an L-arginine dependent and L-NAME sensitive pathway. FASEB J 1995; 9: A327.
Kaesemeyer WH, Abou-Mohamed G, Crute TD, Caldwell RW. Nitrates supplemented with L-arginine for the reversal and treatment of nitrate tolerance: two case reports. Appl Cardiopulm Physiol 1997; 1–8.
Böger RH, Bode-Böger SM, Kienke S, Stan AC, Nafe R, Frolich JC. Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis 1998; 136: 67–77.
Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscl Thromb 1994; 14: 753–759.
Houston M, Chumley P, Radi R, Rubbo H, Freeman BA. Xanthine oxidase reaction with nitric oxide and peroxynitrite. Arch Biochem Biophys 1998; 355: 1–8.
Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992; 267: 24173–24176.
Klatt P, Pfeiffer S, List BM, Lehner D, Glatter O, Bachinger HP, et al. Characterization of hemedeficient neuronal nitric-oxide synthase reveals a role for heme in subunit dimerization and binding of the amino acid substrate and tetrahydrobiopterin. J Biol Chem 1996; 271: 7336–7442.
Wang BY, Singer AH, Tsao PS, Drexler H, Kosek J, Cooke JP. Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. J Am Coll Cardiol 1994; 23: 452–458.
Adams MR, Jessup W, Hailstones D, Celermajer DS. L-arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 1997; 95: 662–668.
Bath PM. The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol 1993; 45: 53–58.
Tsao PS, Buitrago R, Chan JR, Cooke JP. Fluid flow inhibits endothelial adhesiveness. Nitric oxide and transcriptional regulation of VCAM-1. Circulation 1996; 94: 1682–1689.
Mami N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, et al. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866–1874.
Theilmeier G, Chan JR, Zalpour C, Anderson B, Wang BY, Wolf A, et al. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arteriosc Thromb Vasc Biol 1997; 17: 3557–3564.
Ichiki K, Ikeda H, Haramaki N, Ueno T, Imaizumi T. Long-term smoking impairs platelet-derived nitric oxide release. Circulation 1996; 94: 3109–3114.
Cadwgan TM, Benjamin N. Evidence for altered platelet nitric oxide synthesis in essential hypertension. J Hypertens 1993; 11: 417–420.
Wolf A, Zalpour C, Theilmeier G, Wang BY, Ma A, Anderson B, et al. Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans. J Am Coll Cardiol 1997; 29: 479–485.
Adams MR, Forsyth CJ, Jessup W, Robinson J, Celermajer DS. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. J Am Coll Cardiol 1995; 26: 1054–1061.
Bode-Böger SM, Böger RH, Creutzig A, Tsikas D, Gutzki FM, Alexander K, et al. L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Colch) 1994; 87: 303–310.
Marietta M, Facchinetti F, Neri I, Piccinini F, Volpe A, Torelli G. L-arginine infusion decreases platelet aggregation through an intraplatelet nitric oxide release. Thromb Res 1997; 88: 229–235.
Valiance P, Benjamin N, Collier J. The effect of endothelium-derived nitric oxide on ex vivo whole blood platelet aggregation in man. Eur J Clin Pharmacol 1992; 42: 37–41.
Bode-Böger SM, Boger RH, Galland A, Frolich JC. Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 143–150.
Michel T, Smith TW. Nitric oxide synthases and cardiovascular signaling. Am Coll Cardiol 1993; 72: 33C - 38C.
Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res 1989; 65: 1798–1803.
Mendez JD, Zarzoza E. Inhibition of platelet aggregation by L-arginine and polyamines in alloxan treated rats. Biochem Molec Biol Int 1997; 43: 311–318.
Dambisya YM, Lee TL. A thromboelastography study on the in vitro effects of L-arginine and L-NGnitro arginine methyl ester on human whole blood coagulation and fibrinolysis. Blood Coag Fibrin 1996; 7: 678–683.
Udvardy M, Posan E, Palatka K, Altorjay I, Harsfalvi J. Effect of L-arginine on in vitro plasmingeneration and fibrinogenolysis. Thromb Res 1997; 87: 75–82.
Gryglewski RJ, Grodzinska L, Kostka-Trabka E, Korbut R, Bieroon K, Goszcz A, et al. Treatment with L-arginine is likely to stimulate generation of nitric oxide in patients with peripheral arterial obstructive disease. Wien Klin Wochenschr 1996; 108: 111–116.
Marfella R, Acampora R, Verrazzo G, Ziccardi P, De Rosa N, Giunta R, et al. Metformin improves hemodynamic and rheological responses to L-arginine in NIDDM patients. Diabetes Care 1996; 19: 934–939.
Lou H, Kodama T, Wang YN, Katz N, Ramwell P, Foegh ML. L-arginine prevents heart transplant arteriosclerosis by modulating the vascular cell proliferative response to insulin-like growth factor-I and interleukin-6 J Heart Lung Transplant 1996; 15: 1248–1257.
Katan MB, Vroomen LH, Hermus RJ. Reduction of casein-induced hypercholesterolaemia and atherosclerosis in rabbits and rats by dietary glycine, arginine and alanine. Atherosclerosis 1982; 43: 381–391.
Hamon M, Vallet B, Bauters C, Wernert N, McFadden EP, Lablanche JM, et al. Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994; 90: 1357–1362.
Wang BY, Candipan RC, Arjomandi M, Hsiun PT, Tsao PS, Cooke JP. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J Am Coll Cardiol 1996; 28: 1573–1579.
Davies MG, Kim JH, Dalen H, Makhoul RG, Svendsen E, Hagen PO. Reduction of experimental vein graft intimal hyperplasia and preservation of nitric oxide-mediated relaxation by the nitric oxide precursor L-arginine Surgery 1994; 116: 557–568.
Okazaki J, Komori K, Kawasaki K, Eguchi D, Ishida M, Sugimachi K. L-arginine inhibits smooth muscle cell proliferation of vein graft intimai thickness in hypercholesterolemic rabbits. Cardiovasc Res 1997; 36: 429–436.
Dattilo JB, Dattilo MP, Crane JT, Yager DR, Makhoul RG. The nitric oxide precursor L-arginine reduces expression of hyaluronan synthase in experimental vein bypass grafts. J Surg Res 1998; 74: 39–42.
Pipili-Synetos E, Sakkoula E, Maragoudakis ME. Nitric oxide is involved in the regulation of angiogenesis. Br J Pharmacol 1993; 108: 855–857.
Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131–3139.
van der Zee R, Murohara T, Luo Z, Zollmann F, Passeri J, Lekutat C, et al. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95: 1030–1037.
Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101: 2567–2578.
Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95: 1747–1755.
Hirooka Y, Egashira K, Imaizumi T, Tagawa T, Kai H, Sugimachi M, et al. Effect of L-arginine on acetylcholine-induced endothelium-dependent vasodilation differs between the coronary and forearm vasculatures in humans. J Am Coll Cardiol 1994; 24: 948–955.
Otsuji S, Nakajima O, Waku S, Kojima S, Hosokawa H, Kinoshita I, et al. Attenuation of acetylcholine-induced vasoconstriction by L-arginine is related to the progression of atherosclerosis. Am Heart J 1995; 129: 1094–1100.
Lekakis J, Papamichael C, Agrios N, Vemmos A, Voutsas S, Stamatelopoulos S, et al. Peripheral vascular endothelial dysfunction in patients with microvascular angina pectoris. J Am Coll Cardiol 1997; 29: 175A.
Egashira K, Hirooka Y, Kuga T, Mohri M, Takeshita A. Effects of L-arginine supplementation on endothelium-dependent coronary vasodilation in patients with angina pectoris and normal coronary arteriograms. Circulation 1996; 94: 130–134.
Lerman A, Burnett JC Jr, Higano ST, McKinley LJ, Holmes DR Jr. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123–2128.
Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331–333.
Ceremuzynski L, Tomasz C, Herbaczynska-Cedro K. L-arginine improves exercise capacity in patients with stable angina. J Am Coll Cardiol 1997; 29: 157A.
Böger R, Bode-Böger SM, Thiele W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1998; 95: 2068–2074.
Mehta S, Stewart DJ, Levy RD. The hypotensive effect of L-arginine is associated with increased expired nitric oxide in humans. Chest 1996; 109: 1550–1555.
Bijlsma JA, Rabelink AJ, Kaasjager KA, Koomans HA. L-arginine does not prevent the renal effects of endothelin in humans. J Am Soc Nephrol 1995; 5: 1508–1516.
Hishikawa K, Nakaki T, Tsuda M, Esumi H, Ohshima H, Suzuki H, et al. Effect of systemic L-arginine administration on hemodynamics and nitric oxide release in man. Jpn Heart J 1992; 33: 41–48.
Giugliano D, Marfella R, Verrazzo G, Acampora R, Nappo F, Ziccardi P, et al. L-arginine for testing endothelium-dependent vascular functions in health and disease. Am J Physiol 1997; 273: E606 - E612.
Harima A, Shimizu H, Takagi H. Analgesic effect of L-arginine in patients with persistent pain. Eur Neuropsychopharmacol 1991; 1: 529–533.
Nakaki T, Hishikawa K, Suzuki H, Saruta T, Kato R. L-arginine-induced hypotension. Lancet 1990; 336: 696.
Kanno K, Hirata Y, Emori T, Ohta K, Eguchi S, Imai T, et al. L-arginine infusion induces hypotension and diuresis/natriuresis with concomitant increased urinary excretion of nitrite/nitrate and cyclic GMP in humans. Clin Exp Pharmacol Phys 1992; 19: 619–625.
Hishikawa K, Nakaki T, Suzuki H, Kato R, Saruta T. Role of L-arginine-nitric oxide pathway in hypertension. J Hypertens 1993; 11: 639–645.
Hishikawa K, Nakaki T, Suzuki H, Saruta T, Kato R. L-arginine-induced hypotension. Lancet 1991; 337: 683, 684.
Laghi Pasini F, Frigerio C, Blardi P, Domini L, De Giorgi L, Borgogni G, et al. Evidence of an adenosine-dependent mechanism in the hypotensive effect of L-arginine in man. Clin Exp Pharmacol Physiol 1995; 22: 254–259.
Petros AJ, Hewlett AM, Bogle RG, Pearson JD. L-arginine-induced hypotension. Lancet 1991; 337: 1044, 1045.
Chen PY, St. John PL, Kirk KA, Abrahamson DR, Sanders PW. Hypertensive nephrosclerosis in the Dahl/Rapp rat. Initial sites of injury and effect of dietary L-arginine supplementation. Lab Invest 1993; 68: 174–184.
Chen PY, Sanders PW. L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest 1991; 88: 1559–1567.
Turner SW, Wen C, Li M, Whitworth JA. L-arginine prevents corticotropin-induced increases in blood pressure in the rat. Hypertension 1996; 27: 184–189.
Laurant P, Demolombe B, Berthelot. Dietary L-arginine attenuates blood pressure in mineralocorticoid-salt hypertensive rats. Clin Exp Hypertens 1995; 17: 1009–1024.
Matsuoka H, Nakata M, Kohno K, Koga Y, Nomura G, Toshima A. Chronic L-arginine administration attenuates cardiac hypertrophy in spontaneously hypertensive rats. Hypertension 1996; 27: 14–18.
Tomohiro A, Kimura S, He H, Fujisawa Y, Nishiyama A, Kiyomoto K, et al. Regional blood flow in Dahl-Iwai salt-sensitive rats and the effects of dietary L-arginine supplementation. Am J Physiol 1997; 272: R1013 - R1019.
Li M, Fraser T, Wang J, Whitworth JA. Dexamethasone-induced hypertension in the rat: effects of L-arginine. Clin Exp Pharmacol Physiol 1997; 24: 730–732.
Helmbrecht GD, Farhat MY, Lochbaum L, Brown HE, Yadgarova KT, Eglinton GS, et al. L-arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Am J Obstet Gynecol 1996; 175: 800–805.
Pucci ML, Dick LB, Miller KB, Smith CJ, Nasjletti A. Enhanced responses to L-arginine in aortic rings from rats with angiotensin-dependent hypertension. J Pharmacol Exp Therap 1995; 274: 1–7.
Ding Y, Vaziri ND, Gonick HC. Lead-induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside. Environ Res 1998; 76: 107–113.
Jimbo M, Suzuki H, Ichikawa M, Kumagai K, Nishizawa M, Saruta T. Role of nitric oxide in regulation of baroreceptor reflex. J Auton Nerve Sys 1994; 50: 209–219.
Higashi Y, Oshima T, Sasaki N, Ishioka N, Nakano Y, Ozono R, et al. Relationship between insulin resistance and endothelium-dependent vascular relaxation in patients with essential hypertension. Hypertension 1997; 29: 280–285.
Matsuoka H, Itoh S, Kimoto M, Kohno K, Tamai O, Wada Y, et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242–247.
Haulica I, Cosovanu A, Ungureanu G, Zaharia D, Baltatu O, Boisteanu D. Cardiovascular effects of L-arginine as physiological precursor of nitric oxide. Rom J Int Med 1994; 32: 195–201.
Pedrinelli R, Ebel M, Catapano G, Dell’Orno G, Ducci M, Del Chicca M, et al. Pressor, renal and endocrine effects of L-arginine in essential hypertensives. Eur J Clin Pharmacol 1995; 48: 195–201.
Wideman RF Jr, Kirby YK, Ismail M, Bottje WG, Moore RW, Vardeman RC. Supplemental L-arginine attenuates pulmonary hypertension syndrome (ascites) in broilers. Poult Sci 1995; 74: 323–330.
Mitani Y, Maruyama K, Sakurai M. Prolonged administration of L-arginine ameliorates chronic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 1997; 96: 689–697.
Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214–221.
Vosatka RJ, Kashyap S, Trifiletti RR. Arginine deficiency accompanies persistent pulmonary hypertension of the newborn. Biol Neonate 1994; 66: 65–70.
Castillo L, DeRojas-Walker T, Yu YM, Sanchez M, Chapman TE, Shannon D, et al. Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension. Pediatr Res 1995; 38: 17–24.
Stewart DJ. Endothelial dysfunction in pulmonary vascular disorders. Arzneimittel-Forschung 1994; 44: 451–454.
Baudouin SV, Bath P, Martin JF, Du Bois R, Evans TW. L-arginine infusion has no effect on systemic haemodynamics in normal volunteers, or systemic and pulmonary haemodynamics in patients with elevated pulmonary vascular resistance. Br J Clin Pharmacol 1993; 36: 45–49.
Katz SD, Krum H, Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996; 28: 585–590.
Takeshita A, Hirooka Y, Imaizumi T. Role of endothelium in control of forearm blood flow in patients with heart failure. J Cardiac Fail 1996; 2: 5209–5215.
Drexler H, Hayoz D, Munzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596–1601.
Koifman B, Wollman Y, Bogomolny N, Chernichowsky T, Finkelstein A, Per G, et al. Improvement of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol 1995; 26: 1251–1256.
Howes TQ, Keilty SE, Maskrey VL, Deane CR, Baudouin SV, Moxham J. Effect of L-arginine on renal blood flow in normal subjects and patients with hypoxic chronic obstructive pulmonary disease. Thorax 1996; 51: 516–519.
Morikawa E, Moskowitz MA, Huang Z, Yoshida T, Irikura K, Dalkara T. L-arginine infusion promotes nitric oxide-dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke 1994; 25: 429–435.
Sadoshima S, Nagao T, Okada Y, Fujii K, Ibayashi S, Fujishima M. L-arginine ameliorates recirculation and metabolic derangement in brain ischemia in hypertensive rats. Brain Res 1997; 744: 246–252.
DeWitt DS, Smith TG, Deyo DJ, Miller KR, Uchida T, Prough DS. L-arginine and superoxide dismutase prevent or reverse cerebral hypoperfusion after fluid-percussion traumatic brain injury. J Neurotrauma 1997; 14: 223–233.
Prado R, Watson BD, Zhao W, Yao H, Busto R, Dietrich WD, et al. L-arginine does not improve cortical perfusion or histopathological outcome in spontaneously hypertensive rats subjected to distal middle cerebral artery photothrombotic occlusion. J Cereb Blood Flow Metab 1996; 16: 612–622.
Kirsch JR, Bhardwaj A, Martin LJ, Hanley DF, Traystman RJ. Neither L-arginine nor L-NAME affects neurological outcome after global ischemia in cats. Stroke 1997; 28: 2259–2264.
Nakagomi T, Kanemitsu H, Takagi K, Morikawa E, Kirino T, Tamura A. Effect of L-arginine and NGnitro-L-arginine on delayed neuronal death in the gerbil hippocampus. Neurol Res 1997; 19: 426–430.
Huang Z, Huang PL, Ma J, Meng W, Ayata C, Fishman MC, et al. Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine. J Cereb Blood Flow Metab 1996; 16: 981–987.
Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke 1997; 28: 1283–1288.
Wang QD, Morcos E, Wiklund P, Pernow J. L-arginine enhances functional recovery and Ca2+dependent nitric oxide synthase activity after ischemia and reperfusion in the rat heart. J Cardiovasc Pharmacol 1997; 29: 291–296.
Wang P, Zweier JL. Ischemic preconditioning decreases nitric oxide (NO) formation and NO mediated injury in the postischemic heart. Circulation 1997; 96: I - 72.
Li XS, Uriuda Y, Wang QD, Norlander R, Sjoquist PO, Pernow J. Role of L-arginine in preventing myocardial and endothelial injury following ischaemia/reperfusion in the rat isolated heart. Acta Physiol Scand 1996; 156: 37–44.
Brunner F, Leonhard B, Kukovetz WR, Mayer B. Role of endothelin, nitric oxide and L-arginine release in ischaemia/reperfusion injury of rat heart. Cardiovasc Res 1997; 36: 60–66.
Weyrich AS, Ma XL, Lefer AM. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation 1992; 86: 279–288.
Nakanishi K, Vinten-Johansen J, Lefer DJ, Zhao Z, Fowler WC, McGee DS, et al. Intracoronary L-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol 1992; 263: H1650 - H1658.
Takeuchi K, Takashima K, Suzuki S, Fukui K. [Basic amino acid, L-arginine aggravates ischemiareperfusion injury]. Nippon Kyobu Geka Gakkai Zasshi 1996; 44: 155–161.
Fei L, Baron AD, Henry DP, Zipes DP. Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: nitric oxide modulates sympathetic effects on ventricular electrophysiological properties. Circulation 1997; 96: 4044–4049.
Burra P, Ferraresso M, Cadrobbi R, Calabrese F, Crdin R, Parnigotto A, et al. Effect of L-arginine and oligotide on liver ischemia-reperfusion injury. Transplant Proc 1997; 29: 2992–2993.
Shiraishi M, Kusano T, Aihara T, Ikeda Y, Koyama Y, Muto Y. Protection against hepatic ischemia/ reperfusion injury by exogenous L-arginine. Transplant Proc 1996; 28: 1887–1888.
Calabrese F, Valente M, Pettenazzo E, Ferraresso M, Burra P, Cadrobbi R, et al. The protective effects of L-arginine after liver ischaemia/reperfusion injury in a pig model. J Pathol 1997; 183: 477–485.
Shiraishi M, Hiroyasu S, Nagahama M, Miyaguni T, Higa T, Tomori H, et al. Role of exogenous L-arginine in hepatic ischemia-reperfusion injury. J Surg Res 1997; 69: 429–434.
Hiramatsu T, Forbess JM, Miura T, Roth SJ, Cioffi MA, Mayer JE Jr. Effects of endothelin-1 and L-arginine after cold ischemia in lamb hearts. Ann Thorac Surg 1997; 61: 36–40.
Duke T, South M, Stewart A. Altered activation of the L-arginine nitric oxide pathway during and after cardiopulmonary bypass. Perfusion 1997; 12: 405–410.
Stowe DF, Boban M, Roerig DL, Chang D, Palmisano BW, Bosnjak ZJ. Effects of L-arginine and N omega-nitro-L-arginine methyl ester on cardiac perfusion and function after 1-day cold preservation of isolated hearts. Circulation 1997; 95: 1623–1634.
Hiramatsu T, Forbess JM, Miura T, Mayer JE Jr. Effect of L-arginine cardioplegia on recovery of neonatal lamb hearts after 2 hours of cold ischemia. Ann Thorac Surg 1995; 60: 1187–1192.
Hiramatsu T, Forbess JM, Miura T, Mayer JE Jr. Effects of L-arginine and L-nitro-arginine methyl ester on recovery of neonatal lamb hearts after cold ischemia. Evidence for an important role of endothelial production of nitric oxide. J Thorac Cardiovasc Surg 1995; 109: 81–86.
Szabo G, Bahrle S, Dengler TJ, Batkai S, Vahl CF, Hagl S. [Reducing perfusion damage after heart transplantation with the nitric oxide donor L-arginine]. Langenbecks Arch Chir Supplement Kongressbd 1997; 114: 7–10.
Normandin L, Herve P, Brink C, Chapelier AR, Dartevelle PG, Mazmanian GM. L-arginine and pentoxifylline attenuate endothelial dysfunction after lung reperfusion injury in the rabbit. The Paris-Sud University Lung Transplant Group. Ann Thorac Surg 1995; 60: 646–650.
Um SC, Suzuki S, Toyokuni S, Kim BM, Tanaka T, Hiai H, et al. Involvement of nitric oxide in survival of random pattern skin flap. Plast Reconstr Surg 1998; 101: 785–792.
Cordeiro PG, Mastorakos DP, Hu QY, Kirschner RE. The protective effect of L-arginine on ischemiareperfusion injury in rat skin flaps. Plastic Reconst Surg 1997; 100: 1227–1233.
Ercocen AR, Apaydin I, Emiroglu M, Gultan SM, Ergun H, Yormuk E. The effects of L-arginine and iloprost on the viability of random skin flaps in rats. Scand J Plast Reconstr Surg Hand Surg 1998; 32: 19–25.
Walls CM, Gregory CR, Beck LS, Cooke JP, Griffey SM, Kass PH. Effects of growth factors and L-arginine on ischemic skin flaps in rats. Vet Surg 1995; 24: 484–491.
Melis MR, Argiolas A. Role of central nitric oxide in the control of penile erection and yawning. Prog Neuropsychopharmacol Biol Psych 1997; 21: 899–922.
Garban H, Vernet D, Freedman A, Rajfer J, Gonzalez-Cadavid N. Effect of aging on nitric oxide-mediated penile erection in rats. Am J Physiol 1995; 268: H467 - H475.
Xie Y, Garban H, Ng C, Rajfer J, Gonzalez-Cadavid NF. Effect of long-term passive smoking on erectile function and penile nitric oxide synthase in the rat. J Urol 1997; 157: 1121–1126.
Vernet D, Cai L, Garban H, Babbitt ML, Murray FT, Rajfer J, et al. Reduction of penile nitric oxide synthase in diabetic BB/WORdp (type I) and BBZ/WORdp (type II) rats with erectile dysfunction. Endocrinology 1995; 136: 5709–5717.
Kim YC, Davies MG, Hagen PO, Carson CC. Experimental evidence for endothelium dependent relaxation and neuronal nitric oxide in corpus cavernosum. Yonsei Med J 1994; 35: 308–313.
Penson DF, Ng C, Rajfer J, Gonzalez-Cadavid NF. Adrenal control of erectile function and nitric oxide synthase in the rat penis. Endocrinology 1997; 138: 3925–3932.
Kimura K, Takahashi M, Naroda T, Iriguchi H, Miyamoto T, Kawanishi Y, et al. [The relaxation of human corpus cavernosum caused by nitric oxide]. Nippon Hinyokika Gakkai Zasshi 1993; 84: 1660–1664.
Simonsen U, Prieto D, Delgado JA, Hernandez M, Resel L, Saenz de Tejada I, et al. Nitric oxide is involved in the inhibitory neurotransmission and endothelium-dependent relaxations of human small penile arteries. Clin Sci (Colch) 1997; 92: 269–275.
Benelli A, Bertolini A, Poggioli R, Cavazzuti E, Calza L, Giardino L, et al. Nitric oxide is involved in male sexual behavior of rats. Eur J Pharmacol 1995; 294: 505–510.
Luscher TF, Bock HA. The endothelial L-arginine/nitric oxide pathway and the renal circulation. Klin Wochenschr 1991; 69: 603–609.
De Nicola L, Minutolo R, Bellizzi V, Andreucci M, La Verde A, Cianciaruso B. Enhancement of nitric oxide synthesis by L-arginine supplementation in renal disease: is it good or bad? Miner Electrolyte Metab 1997; 23: 144–150.
Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF. Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol 1994; 4: 1690–1694.
Ashab I, Peer G, Blum M, Wollman Y, Chernihovsky T, Hassner A, et al. Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 1995; 47: 1515–1521.
Wakabayashi Y, Kikawada R. Effect of L-arginine on myoglobin-induced acute renal failure in the rabbit. Am J Physiol 1996; 270: F784 - F789.
De Nicola L, Thomson SC, Wead LM, Brown MR, Gabbai FB. Arginine feeding modifies cyclosporine nephrotoxicity in rats. J Clin Invest 1993; 92: 1859–1865.
Kumagai K, Suzuki H, Ichikawa M, Jimbo M, Murakami M, Ryuzaki M, et al. Nitric oxide increases renal blood flow by interacting with the sympathetic nervous system. Hypertension 1994; 24: 220–226.
Aiello S, Noris M, Remuzzi G. Nitric oxide synthesis and L-arginine in uremia. Miner Electrolyte Metab 1997; 23: 151–156.
Reyes AA, Klahr S. Dietary supplementation of L-arginine ameliorates renal hypertrophy in rats fed a high-protein diet. Proc Soc Exp Biol Med 1994; 206: 157–161.
Thomas SE, Andoh TF, Pichler RH, Shankland SJ, Couser WG, Bennett WM, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53: 897–908.
Yang CW, Kim YS, Kim J, Kim YO, Min SY, Choi EJ, et al. Oral supplementation of L-arginine prevents chronic cyclosporine nephrotoxicity in rats. Exp Nephrol 1998; 6: 50–56.
Assis SM, Monteiro JL, Seguro AC. L-Arginine and allopurinol protect against cyclosporine nephrotoxicity. Transplantation 1997; 63: 1070–1073.
MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephr Dialys Transplant 1996; 11: 2449–2452.
Andres A, Morales JM, Praga M, Campo C, Lahera V, Garcia-Robles R, et al. L-arginine reverses the antinatriuretic effect of cyclosporin in renal transplant patients. Nephrol Dialys Transplant 1997; 12: 1437–1440.
Creager MA, Halperin JL, Coffman, JD. Vasospastic diseases. In: Loscalzo J, Creager MA, Dzau VJ, eds. The Textbook of Vascular Medicine. Little Brown, Boston, 1992, pp. 975–1010.
Coffman JD, Davies WT. Vasospastic disease: a review. Prog Cardiovasc Dis 1975; 18: 123–146.
Robertson D, Oates JA. Variant angina and Raynaud’s phenomenon. Lancet 1978; 1: 452.
Flavahan NA Human postjunctional alpha 1 and alpha 2-adrenoceptors: differential distribution in arteries of the limbs. J Pharmacol Exp Ther 1986;241:361–365.
Moulds RF, Iwanov V, Medcalf RL. The effects of platlet-derived contractile agents on human digital arteries. Clin Sci 1984; 66: 443–451.
Coffman JD, Cohen RA. Serotoninergic vasoconstriction in human fingers during reflex sympathetic responses to cooling. Am J Physiol 1988; 254: H889 - H893.